Agenus Inc. (NASDAQ:AGEN) Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC trimmed its holdings in shares of Agenus Inc. (NASDAQ:AGEN) by 95.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 254,329 shares of the biotechnology company’s stock after selling 5,161,386 shares during the period. Renaissance Technologies LLC’s holdings in Agenus were worth $4,260,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in AGEN. Hennion & Walsh Asset Management Inc. lifted its stake in Agenus by 2.5% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 558,606 shares of the biotechnology company’s stock worth $324,000 after purchasing an additional 13,604 shares during the last quarter. Ovata Capital Management Ltd acquired a new stake in Agenus during the second quarter worth approximately $670,000. Crestline Management LP lifted its position in shares of Agenus by 6.5% during the 4th quarter. Crestline Management LP now owns 708,480 shares of the biotechnology company’s stock worth $587,000 after buying an additional 43,480 shares during the last quarter. Powell Investment Advisors LLC boosted its holdings in shares of Agenus by 21.8% in the 1st quarter. Powell Investment Advisors LLC now owns 243,500 shares of the biotechnology company’s stock valued at $141,000 after buying an additional 43,500 shares in the last quarter. Finally, Ables Iannone Moore & Associates Inc. acquired a new position in shares of Agenus in the 4th quarter valued at $65,000. 61.46% of the stock is owned by institutional investors and hedge funds.

Agenus Stock Performance

Agenus stock opened at $5.31 on Friday. The stock has a 50-day simple moving average of $5.53 and a 200-day simple moving average of $9.99. The company has a market capitalization of $111.50 million, a P/E ratio of -0.41 and a beta of 1.36. Agenus Inc. has a fifty-two week low of $4.41 and a fifty-two week high of $23.40.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($2.52) EPS for the quarter, missing the consensus estimate of ($1.33) by ($1.19). The business had revenue of $23.51 million during the quarter, compared to analysts’ expectations of $64.73 million. During the same period in the previous year, the company posted ($4.00) earnings per share. As a group, analysts forecast that Agenus Inc. will post -10.87 earnings per share for the current year.

Wall Street Analyst Weigh In

AGEN has been the subject of a number of research reports. HC Wainwright cut shares of Agenus from a “buy” rating to a “neutral” rating and reduced their price target for the company from $40.00 to $9.00 in a research report on Thursday, July 18th. William Blair downgraded Agenus from an “outperform” rating to a “market perform” rating in a report on Thursday, July 18th. Robert W. Baird downgraded Agenus from an “outperform” rating to a “neutral” rating and reduced their target price for the company from $35.00 to $8.00 in a report on Friday, July 19th. Jefferies Financial Group reissued a “hold” rating and issued a $7.00 target price (up from $3.00) on shares of Agenus in a report on Friday, July 19th. Finally, Baird R W downgraded Agenus from a “strong-buy” rating to a “hold” rating in a report on Friday, July 19th. One analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Agenus presently has a consensus rating of “Hold” and a consensus price target of $10.50.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.